The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
MD Douglas S Corwin, Peter T Ender, Nitasa Sahu, Ryan A Durgham, Dennis M Mcgorry Jr, Awan Rahman, Jill Stoltzfus, Jeffrey A Jahre
Open Forum Infectious Diseases, doi:10.1093/ofid/ofab305
Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 . This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.
Author contributions. D.S.C., P.E., N.S., R.D., and J.S. drafted the initial manuscript. All authors reviewed, contributed to the revision and approved the final manuscript. D.S.C. had full access to manuscript and final responsibility to submit for publication.
References
Bowden, Hospitals face severe shortages as pandemic grinds forward. The Hill
Chen, Nirula, Heller, BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med
Goldhill, Hospitals in half the states are facing a massive staffing shortage, STAT
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Halpin, Criner, Papi, Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD Science Committee report on COVID-19 and chronic obstructive pulmonary disease, Am J Respir Crit Care Med
Jorden, Rudman, Evidence for limited early spread of COVID-19 within the United States, MMWR Morb Mortal Wkly Rep
Kane, Shamliyan, Mueller, Nurse staffing and quality of patient care, Evid Rep Technol Assess (Full Rep)
Leatherby, Keefe, Tompkins, There's no place for them to go': I.C.U. beds near capacity across U.S. The New York Times
O'hearn, Liu, Cudhea, Coronavirus disease 2019 hospitalizations attributable to cardiometabolic conditions in the United States: a comparative risk assessment analysis, J Am Heart Assoc
Wang, Nair, Liu, Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization
Wickham, R packages for data science
Widera, Wilhelm, Hoehl, Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro
DOI record:
{
"DOI": "10.1093/ofid/ofab305",
"ISSN": [
"2328-8957"
],
"URL": "http://dx.doi.org/10.1093/ofid/ofab305",
"abstract": "<jats:title>Abstract</jats:title>\n <jats:p>Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.</jats:p>",
"author": [
{
"affiliation": [
{
"name": "Section of Pulmonary and Critical Care, Department of Medicine, St Luke’s University Health Network, Bethlehem, Pennsylvania, USA"
}
],
"family": "Corwin",
"given": "Douglas S",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Section of Infectious Diseases, Department of Medicine, St. Luke’s University Health Network, Bethlehem, Pennsylvania, USA"
}
],
"family": "Ender",
"given": "Peter T",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Section of Pulmonary and Critical Care, Department of Medicine, St Luke’s University Health Network, Bethlehem, Pennsylvania, USA"
}
],
"family": "Sahu",
"given": "Nitasa",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Temple/St. Luke’s School of Medicine, Bethlehem, Pennsylvania, USA"
}
],
"family": "Durgham",
"given": "Ryan A",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Family Medicine, St. Luke’s University Health Network, Bethlehem, Pennsylvania, USA"
}
],
"family": "McGorry",
"given": "Dennis M",
"sequence": "additional",
"suffix": "Jr."
},
{
"affiliation": [
{
"name": "Section of Pulmonary and Critical Care, Department of Medicine, St Luke’s University Health Network, Bethlehem, Pennsylvania, USA"
}
],
"family": "Rahman",
"given": "Awan",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Graduate Medical Education, Data Management and Outcomes Assessment, St. Luke’s University Health Network, Bethlehem, Pennsylvania, USA"
}
],
"family": "Stoltzfus",
"given": "Jill",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Section of Infectious Diseases, Department of Medicine, St. Luke’s University Health Network, Bethlehem, Pennsylvania, USA"
}
],
"family": "Jahre",
"given": "Jeffrey A",
"sequence": "additional"
}
],
"container-title": "Open Forum Infectious Diseases",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
6,
10
]
],
"date-time": "2021-06-10T16:08:25Z",
"timestamp": 1623341305000
},
"deposited": {
"date-parts": [
[
2021,
7,
11
]
],
"date-time": "2021-07-11T19:21:36Z",
"timestamp": 1626031296000
},
"indexed": {
"date-parts": [
[
2023,
5,
8
]
],
"date-time": "2023-05-08T07:50:10Z",
"timestamp": 1683532210332
},
"is-referenced-by-count": 5,
"issue": "7",
"issued": {
"date-parts": [
[
2021,
6,
10
]
]
},
"journal-issue": {
"issue": "7",
"published-print": {
"date-parts": [
[
2021,
7,
1
]
]
}
},
"language": "en",
"license": [
{
"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
6,
10
]
],
"date-time": "2021-06-10T00:00:00Z",
"timestamp": 1623283200000
}
}
],
"link": [
{
"URL": "http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab305/38576790/ofab305.pdf",
"content-type": "application/pdf",
"content-version": "am",
"intended-application": "syndication"
},
{
"URL": "http://academic.oup.com/ofid/article-pdf/8/7/ofab305/38897252/ofab305.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "syndication"
},
{
"URL": "http://academic.oup.com/ofid/article-pdf/8/7/ofab305/38897252/ofab305.pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "286",
"original-title": [],
"prefix": "10.1093",
"published": {
"date-parts": [
[
2021,
6,
10
]
]
},
"published-online": {
"date-parts": [
[
2021,
6,
10
]
]
},
"published-other": {
"date-parts": [
[
2021,
7,
1
]
]
},
"published-print": {
"date-parts": [
[
2021,
7,
1
]
]
},
"publisher": "Oxford University Press (OUP)",
"reference": [
{
"DOI": "10.15585/mmwr.mm6922e1",
"article-title": "Evidence for limited early spread of COVID-19 within the United States, January – February 2020",
"author": "Jorden",
"doi-asserted-by": "crossref",
"first-page": "680",
"journal-title": "MMWR Morb Mortal Wkly Rep",
"key": "2021071119212397000_CIT0001",
"volume": "69",
"year": "2020"
},
{
"key": "2021071119212397000_CIT0002"
},
{
"author": "Leatherby",
"key": "2021071119212397000_CIT0003",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2029849",
"article-title": "SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19",
"author": "Chen",
"doi-asserted-by": "crossref",
"first-page": "229",
"journal-title": "N Engl J Med",
"key": "2021071119212397000_CIT0004",
"volume": "384",
"year": "2021"
},
{
"DOI": "10.1001/jama.2021.0202",
"article-title": "Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial",
"author": "Gottlieb",
"doi-asserted-by": "crossref",
"first-page": "632",
"journal-title": "JAMA",
"key": "2021071119212397000_CIT0005",
"volume": "325",
"year": "2021"
},
{
"author": "Wickham",
"key": "2021071119212397000_CIT0006"
},
{
"DOI": "10.1161/JAHA.120.019259",
"article-title": "Coronavirus disease 2019 hospitalizations attributable to cardiometabolic conditions in the United States: a comparative risk assessment analysis",
"author": "O’Hearn",
"doi-asserted-by": "crossref",
"first-page": "e019259",
"journal-title": "J Am Heart Assoc",
"key": "2021071119212397000_CIT0007",
"volume": "10",
"year": "2021"
},
{
"DOI": "10.1164/rccm.202009-3533SO",
"article-title": "Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD Science Committee report on COVID-19 and chronic obstructive pulmonary disease",
"author": "Halpin",
"doi-asserted-by": "crossref",
"first-page": "24",
"journal-title": "Am J Respir Crit Care Med",
"key": "2021071119212397000_CIT0008",
"volume": "203",
"year": "2021"
},
{
"article-title": "Nurse staffing and quality of patient care",
"author": "Kane",
"first-page": "1",
"journal-title": "Evid Rep Technol Assess (Full Rep)",
"key": "2021071119212397000_CIT0009",
"year": "2007;"
},
{
"author": "Goldhill",
"key": "2021071119212397000_CIT0010"
},
{
"author": "Bowden",
"key": "2021071119212397000_CIT0011",
"year": "2021"
},
{
"key": "2021071119212397000_CIT0012",
"year": "2021"
},
{
"article-title": "Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization",
"author": "Wang",
"journal-title": "bioRxiv",
"key": "2021071119212397000_CIT0013",
"year": "2021"
},
{
"article-title": "Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro",
"author": "Widera",
"journal-title": "medRxiv",
"key": "2021071119212397000_CIT0014",
"year": "2021"
},
{
"DOI": "10.1001/jama.2021.0202",
"article-title": "Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial",
"author": "Gottlieb",
"doi-asserted-by": "crossref",
"first-page": "632",
"journal-title": "JAMA",
"key": "2021071119212397000_CIT0015",
"volume": "325",
"year": "2021"
}
],
"reference-count": 15,
"references-count": 15,
"relation": {},
"resource": {
"primary": {
"URL": "https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofab305/6295837"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Infectious Diseases",
"Oncology"
],
"subtitle": [],
"title": "The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting",
"type": "journal-article",
"volume": "8"
}
